Impact of poorly controlled type II diabetes mellitus on chemoresistance in colorectal cancer  

作　　者：Aditya Gaur Rick Maity Arkadeep Dhali Jyotirmoy Biswas 

机构地区：[1]Foundation Training Program,Somerset NHS Foundation Trust,Yeovil BA202BX,Somerset,United Kingdom [2]General Medicine,Institute of Post Graduate Medical Education and Research,Kolkata 700020,India [3]Academic Unit of Gastroenterology,Sheffield Teaching Hospitals NHS Foundation Trust,Royal Hallamshire Hospital,Sheffield S102JF,United Kingdom [4]School of Medicine and Population Health,University of Sheffield,Sheffield S102HQ,United Kingdom [5]Deanery of Clinical Sciences,University of Edinburgh,Edinburgh EH164SB,United Kingdom [6]School of Medicine,University of Leeds,Leeds LS29JT,United Kingdom [7]General Medicine,College of Medicine and Sagore Dutta Hospital,Kolkata 700058,India

出　　处：《World Journal of Gastroenterology》2025年第11期216-221,共6页世界胃肠病学杂志(英文)

摘　　要：Type 2 diabetes mellitus(T2DM)significantly elevates the risk of colorectal cancer(CRC)and complicates its treatment by promoting chemoresistance.Poor glycemic control has been linked to exacerbated CRC progression and diminished chemotherapy efficacy,impacting patient outcomes through various mechanisms such as oxidative stress,activation of metabolic pathways,and altered protein modifications that hinder apoptosis and enhance tumor survival.Clinical evidence shows that T2DM patients experience higher rates of chemoresistance and reduced disease-free survival and overall survival compared to non-diabetic patients.Specifically,those with poor glycemic control exhibit increased chemo-resistance and poorer survival metrics.Antidiabetic treatments,including metformin,acarbose,and gliclazide,show promise in improving chemotherapy response and glycemic management,potentially enhancing patient outcomes.Addressing this challenge requires a comprehensive,multidisciplinary approach involving oncologists,endocrino-logists,and surgeons to optimize patient care.Integrated strategies that prioritize glycemic control are essential for reducing chemoresistance and improving survival in CRC patients with T2DM.

关 键 词：Type 2 diabetes mellitus Colorectal cancer Cancer CHEMORESISTANCE Diabetes mellitus HYPERGLYCEMIA CHEMOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]